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Antimicrobial resistance heightens the prospect of readily 
curable infections becoming  pathogens with pandemic 
potential. Although in high-income settings progress has 
been made to curb the rise of resistance,1 the scarcity of 
new antimicrobial drugs remains a challenge. 
The Independent Review on Antimicrobial Resistance, 
launched in 2014, estimated a population reduction by 
2050 of between 11 million and 444 million people in 
a world without eﬀ ective antibiotics, and a reduction 
in the size of the global economy by 0·1–3·1%.2 The US 
Centers for Disease Control and Prevention estimates the 
direct costs of antimicrobial resistance at US$20 billion, 
with additional productivity losses of $35 billion.3 In 
Europe, historical estimates from 2009 suggest a direct 
and indirect cost of €1·5 billion.4 Notwithstanding the 
large discrepancies in these estimates and the wide 
uncertainties, the health, economic, and societal risks of 
antimicrobial resistance are simply too great to be ignored. 
Sometimes diﬃ  cult to conceive in view of their ubiquity 
in health care, antibiotics have only been used routinely 
over the past 75 years. In that time, antibiotics have 
instrumentally shaped the quality of medicine and clinical 
practice that we see today. Beyond health care, antibiotics 
are widely used in the human food system, agriculture, 
and aquaculture.5 Existing strategies to address 
antimicrobial resistance focus on antibiotic prescriptions 
for human beings (both appropriate and inappropriate) 
and consumption by livestock. Regulation of livestock 
consumption is particularly challenging—in China 
and India alone, antibiotic consumption by livestock 
is expected to rise from more than 15 000 tonnes in 
2010 to 40 000 tonnes in 2030.5 Whether eﬀ ective 
mechanisms and policies can be implemented to ensure 
appropriate antibiotic use in livestock remains to be seen. 
The principle of one health will therefore be central to any 
progress in curbing antimicrobial resistance.
Increasingly better quality data exist on the patterns 
of emerging antimicrobial resistance and of antibiotic 
usage. Europe has had success in reducing antimicrobial 
resistance, as documented by the European Anti microbial 
Resistance Surveillance Network.6 For example, cases of 
meticillin-resistant Staphylococcus aureus across hospitals 
in several countries have decreased each year after the 
introduction of infection control practices and local 
hospital guidelines. The level of success varies, however, 
across the 50 countries of the WHO European Region.4,6
Ruth Kelly and colleagues7 report new data to map the 
landscape and pattern of investment in antibacterial 
resistance research. Data from the European Union 
and the Joint Programming Initiative on Antimicrobial 
Resistance (JPIAMR) are included, incorporating public 
funding for research across 17 European countries, 
Canada, and Israel. The ﬁ ndings are revealing; between 
2007 and 2013, €1·3 billion of research investment 
came from public sources, with two-thirds of funding 
earmarked for novel therapeutics, but only €12·5 million 
of that funding was dedicated to the environment and 
€25·1 million to surveillance. A further mismatch shown 
by the study is the substantial variability of national-
level studies; the UK accounted for almost 500 of the 
1208 nationally funded studies, with Canada, the second 
largest contributor, coordinating about 100 studies 
during the same period. 
The results of the study by Kelly and colleagues7 
emphasise both the shortcomings of and hope 
for antimicrobial research funding. However, with 
concerted leadership, all states in the JPIAMR network 
and beyond should be able to reinforce their partnership, 
share best practices, and change the course of the status 
quo. The UK’s leadership to prioritise antimicrobial 
resistance as an important global challenge is translating 
into tangible action,8,9 but the strategy has room for 
improvement. A coordinated, global eﬀ ort combining 
drug resistance, antibiotic pipeline, antibiotic usage, and 
investment data is urgently needed. Kelly and colleagues 
build on the published literature10,11 and provide a basis 
for harmonisation to begin—at the very least on a 
European platform.
As with any research programme, the quality and 
completeness of data are essential, and for these 
analyses to be complete, a real partnership needs to 
exist between public, philanthropic, and private funders. 
These partnerships are particularly important for 
antimicrobial resistance because of market failure,12 the 
dependence on the pharmaceutical industry to deliver 
novel therapeutic drugs, and the social imperative to 
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allocate limited resources responsibly with a sense of 
urgency. Furthermore, research and surveillance needs 
to be expanded beyond Europe, the USA, and Canada 
for antimicrobial resistance to be adequately controlled. 
With antibiotic sales data predicting inﬂ uenza-like 
illness in the USA,13 early point-of-care diagnostics for 
overlapping clinical syndromes should be a priority area, 
particularly in low-income and middle-income settings. 
The global scientiﬁ c and health policy communities 
must rise to the challenge of antimicrobial resistance 
(and opportunity) to develop resilient health systems 
for eﬀ ectively managing resistance, redistribute 
collaborative research studies, and realign investments 
across countries. The human and economic cost of 
playing catch up is simply too great a risk to bear.
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In The Lancet Infectious Diseases, Elizabeth Byrne and 
colleagues1 report the biological mechanism by which 
injec table progestin-only contraceptives, such as 
depot medroxy progesterone acetate (DMPA) and 
norethindrone enanthate (NET-EN), or endogenous 
progesterone might act to increase the risk of HIV 
acquisition in women. They report that HIV-negative 
injectable progestin-only contraceptive users had a 
3·92 times higher frequency of cervical HIV target 
cells than women using no long-term contraceptive 
(p=0·0241), and women using no long-term 
contraceptive in the luteal phase of the menstrual cycle 
(a naturally high-progestin state) also had a 3·25 times 
higher frequency of cervical target cells than those in 
the lower-progestin follicular phase (p=0·0488).
The role of injectable progestin-only contraceptives 
as a risk factor for HIV acquisition has been debated 
for several years.2 Although this question has not been 
addressed in adequately powered randomised controlled 
trials, several secondary analyses3,4 of large randomised 
controlled trials have estimated an increased risk for 
injectable progestin-only contraceptives, some of which 
are able to distinguish between DMPA and NET-EN. An 
individual patient data analysis5 reported a signiﬁ cant 
increase in HIV incidence in women using DMPA, and a 
non-signiﬁ cant increase in this direction for NET-EN. 
WHO convened a special meeting in 2012 to discuss 
the evidence available at the time, resulting in the 
release of a technical statement.6 WHO recommended 
that women receiving injectable progestin-only con-
traceptives should use other HIV prevention methods 
such as male and female condoms in conjunction to 
prevent HIV acquisition. The panel also recommend 
that, ﬁ rst, further consideration should be given to 
high quality research designs to conﬁ rm the role of 
progestin hormonal contraception in HIV acquisition; 
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